KLK3 and neoplasm: Tumor response (14.4% vs 4.4%; P = 0.0005) and PSA response (39.2% vs 17.8%; P = 0.0002) also significantly favored cabazitaxel, as did median time to tumor progression (8.8 vs 5.4 months; P < 0.0001) and median time to PSA progression (6.4 vs 3.1 months; P = 0.001).